Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals

WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's

Related Keywords

United States , Proctitis Proctosigmoiditis , Leo Ehrlich , Innovation Pharmaceuticals Inc , Company Brilacidin Phase , Drug Administration , Antiviral Program For Pandemics , Company Compassionate , Exchange Commission , Brilacidin Antiviral Program , National Early Warning Score , Innovation Pharmaceuticals , Brilacidin Phase , Chief Executive Officer , Sustained Recovery Through Day , Intent To Treat Population , Patient Subgroup , Highest Quartile Baseline Values , Per Protocol Population , C Reactive Protein , Load Biomarker , Compassionate Use , Observed Treatment , Brilacidin Oral Mucositis , Ulcerative Colitis , Looking Statements , Private Securities Litigation Reform Act , Innovation , Pharmaceuticals , Reports , Dditional , Findings , Ased , Review , Brilacidin , Hase , Covid , Trial , Results , Compassionate , Cases ,